Korea JoongAng Daily on MSN2h
Celltrion asthma drug Omlyclo approved for U.S. release
Celltrion said on Monday that its biosimilar Omlyclo had received market authorization for U.S. release. The drug, referencing Xolair, can treat multiple allergic conditions including moderate to ...
Yonhap News Agency on MSN6h
Celltrion gets U.S. approval for allergic asthma biosimilar
Celltrion Inc., a major South Korean biopharmaceutical firm, said Monday its biosimilar for asthma and other chronic allergic diseases has obtained approval for U.S. sales. The U.S. Food and Drug ...